Kiniksa Pharmaceuticals (KNSA)

• Market cap: $3.33B
• 1 day: -0.09%
• 5 days: 4.35%
• 1 month: 7.15%
• 3 months: 17.78%
• 6 months: 46.11%
• Year to date: 4.55%
• 1 year: 120.93%
• 5 years: 111.15%
• 10 years: 125.58%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Employees: 315